
EUSA acquires global rights to Janssen's Sylvant for $115mm
Executive Summary
EUSA Pharma acquired worldwide rights to Sylvant (siltuximab) from Janssen Sciences Ireland UC.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com